Daicel (4202) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
17 Jun, 2026Executive summary
Net sales for 1H FY2025/3 rose 6.9% year-over-year to ¥289.7 billion, with operating income up 18.8% to ¥31.6 billion and net income attributable to owners up 7.7% to ¥32.1 billion, driven by higher engineering plastics sales, cost reductions, and favorable exchange rates.
Growth was supported by increased sales volumes in key product areas, despite global economic uncertainties and mixed demand trends.
Full-year forecasts were revised downward for operating income and net income due to plant issues and automotive sector weakness, but net sales guidance was revised upward year-over-year.
Shareholder returns were strengthened with an annual dividend forecast of 60 yen per share (up 10 yen YoY) and a treasury stock buyback of ¥15 billion.
Financial highlights
1H FY2025/3 net sales: ¥289.7 billion (+6.9% YoY), operating income: ¥31.6 billion (+18.8% YoY), EBITDA: ¥51.3 billion (+22.5% YoY), net income attributable to owners: ¥32.1 billion (+7.7% YoY).
Gross profit increased to ¥84.0 billion from ¥74.9 billion year-over-year.
EPS for the period was ¥116.18, up from ¥104.13 in the prior year.
Comprehensive income fell to ¥24.1 billion from ¥51.0 billion due to negative foreign currency translation adjustments.
Gains from sale of affiliated company shares contributed to net profit.
Outlook and guidance
FY2025/3 full-year net sales forecast revised to ¥600.0 billion (up 7.5% YoY), operating income to ¥60.0 billion, EBITDA to ¥102.5 billion, and net income attributable to owners to ¥51.0 billion (down 8.7% YoY).
EPS forecast revised to ¥184.70.
Interim and year-end dividends each forecast at 30 yen per share, with annual total of 60 yen per share.
Treasury stock buyback of ¥15 billion for 12 million shares planned.
Latest events from Daicel
- Operating income fell 25% year-over-year, but healthcare and mobility segments grew.4202
Q1 202617 Jun 2026 - Sales and profits fell on FX and global headwinds, but cost controls lifted select segment margins.4202
Q2 202617 Jun 2026 - Operating profit nearly doubled on strong demand and favorable exchange rates.4202
Q1 202517 Jun 2026 - Sales rose 5.1%, but profits declined; FY2026 outlook: higher sales, lower profits, stable dividends.4202
Q4 202517 Jun 2026 - Net sales up 4.4% year-over-year, but profit margins declined amid mixed segment results.4202
Q3 202517 Jun 2026 - Profits fell on lower sales, but healthcare and safety segments showed strong growth.4202
Q3 202617 Jun 2026 - Profits fell on impairment losses, but FY2027 net income is forecast to rebound strongly.4202
Q4 202617 Jun 2026